Syndax Announces Participation in November Investor Conferences
Key Highlights
- ➤Syndax management schedules four November investor-conference fireside chats
- ➤Events span Boston, New York, and London from November 10-19, 2026
- ➤Live webcasts and limited-time replays will be available on Syndax's website
- ➤Pipeline includes FDA-approved Revuforj (revumenib) and Niktimvo (axatilimab-csfr)
Expert Statements
Michael A. Metzger, Chief Executive Officer of Syndax Pharmaceuticals
“Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company advancing innovative cancer therapies”
NEW YORK, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: * Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA with a fireside chat on Tuesday, November 10, 2026, at 11:00 a.m. ET. * Stifel 2026 Healthcare Conference in New York, NY with a fireside chat on Thursday, November 12, 2026, at 9:20 a.m. ET. * UBS Global Biopharma Conference 2026 in London, UK with a fireside chat on Tuesday, November 17, 2026, at 12:00 p.m. GMT / 7:00 a.m. ET. * Jefferies London Healthcare Conference in London, UK with a fireside chat on Thursday, November 19, 2026, at 12:30 p.m. GMT / 7:30 a.m. ET. A live webcast of the fireside chats will be available in the Investor section of the Company's website at www.syndax.com, where a replay will also be available for a limited time.
Get started
Create a free account to read the full story.